Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: In the shadow of infliximab?

International Journal of Colorectal Disease

Volumn 18, Issue 1, 2003, Pages 1-11

  Shand, Alan ^a   Forbes, Alastair ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Cytokine; Intercellular adhesion moleculae 1; Interleukin 10; Natalizumab; Ulcerative colitis

Indexed keywords

ALICAFORSEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; INFLIXIMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 PROTEIN INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN INHIBITOR; NATALIZUMAB; NEUTRALIZING ANTIBODY; PREDNISONE; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 10; THALIDOMIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; CROHN DISEASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; GENETIC ENGINEERING; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INJECTION PAIN; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RASH; REVIEW; STROKE; TACHYCARDIA; TH1 CELL; ULCERATIVE COLITIS; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; CROHN DISEASE; CYTOKINES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, CELLULAR;

EID: 0038141739     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-002-0431-6     Document Type: Review

References (100)

1. Podolsky DK (1991) Inflammatory bowel disease. I. N Engl J Med 324:928-937
2. MacDermott RP, Stenson WF (1988) Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 42:285-328
3. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al (2001) Association of NOD2 leucine rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603
4. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen F, Ramos R, et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606
5. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357 1925-1928
6. Sartor RB (1994) Cytokines in intestinal inflammation: pathophysiologic and clinical considerations. Gastroenterology 106:533-539
7. Niessner M, Volk BA (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101:428-435
8. Fais S, Capobianchi MR, Pallone F, Di MArco P, Boirivant M, Dianzani F, et al (1991) Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Gut 32:403-407
9. Fais S, Capobianchi MR, Silvestri M, Mercuri F, Dianzani F, Pallone F (1994) Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Cytokine Res 14:235-238
10. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al (1998) Il-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101:783-794
11. Keystone E, Wherry J, Grint P (1998) Il-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 24:629-639
12. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al (1997) A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337:1029-1035
13. Stack WA, Mann SD, Roy AJ, Heath P, Freeman J, Holmes G, et al (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349:521-524
14. Ricart E, Sandborn WJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. Gastroenterology 117:1247-1248
15. Present DH (1999) Review article: the efficacy of infliximab in Crohn's disease-healing of fistulae. Aliment Pharmacol Ther 13 [Suppl 4]:23-28
16. Schreiber S, Campieri M, Colombel JF, van Deventer SJH, Feagan B, Fedorak RN, et al (2001) Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 16:1-11
17. Baert FJ, Rutgeerts P (1999) Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 14:47-51
18. Brandt E, Colombel JF, Ectors N, Gambiez L, Emilie D, Geboes K, et al (2000) Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). Clin Exp Immunol 122:180-185
19. Grimm MC, Elsbury SK, Pavli P, Doe WF (1996) Interleukin-8: cells of origin in inflammatory bowel disease. Gut 38:90-98
20. Arnott ID, Drummond HE, Ghosh S (2001) Gut mucosal secretion of interleukin-1β and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig Dis Sci 46:402-409
21. Yang XD, Corvalan JRF, Wang P, Roy CMN, Davis CG (1999) Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 66:401-410
22. Osman MO, Kristensen JU, Jacobsen NO, Lausten SB, Deleuran B, Deleuran M, et al (1998) A monoclonal anti-interleukin-8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental acute necrotising pancreatitis in rabbits. Gut 43:232-239
23. Wada T, Tomosugi N, Naito T, Yokoyama H, Kobayashi KI, Harada A, et al (1994) Prevention of proteinuria by the administration of anti-interleukin-8 antibody in experimental acute immune complex-induced glomerulo-nephritis. J Exp Med 180:1135-1140
24. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al (2000) Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 119:1473-1482
25. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al (2000) Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn's disease. Gastroenterology 119:1461-1472
26. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, et al (2001) Interleukin-10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49:42-46
27. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, et al (1999) Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn's disease. Gastroenterology 117:58-64
28. Montefort S, Holgate ST (1991) Adhesion molecules and their role in inflammation. Respir Med 85:91-99
29. Hokari R, Miura S, Fujimoro H, et al (1997) Lymphocyte outflux to to intestinal microlymphatics is an intercellular adhesion molecule-1 dependent process in Peyer's patches (abstract). Gastroenterology 112:A369
30. Adams DH, Hubscher SG, Shaw J, Rothlein R, Neuberger JM (1989) Intercellular adhesion molecule 1 on liver allografts during rejection. Lancet II:1122-1125
31. Faull RJ, Russ GR (1989) Tubular expression of intercellular adhesion molecule 1 during renal allograft rejection. Transplantation 48:226-230
32. Volpes R, van den Oord JJ, Desmet VJ (1990) Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 12:59-65
33. Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH, et al (1995) Adhesion molecules in inflammatory bowel disease. Gut 36:724-730
34. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K (1999) Inhibition of dextran sulphate sodium (DSS) induced colitis in mice by intra-colonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule 1[ELAM-1] or intercellular adhesion molecule 1 [ICAM-1]). Clin Exp Immunol 117:462-468
35. Yacyshyn BR, Shanahan WR Jr (1999) Making sense of antisense. Can J Gastroenterol 13:745-751
36. Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081-2095
37. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274
38. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice. Infect Immun 66:5224-52231
39. Berg DJN, Davidson R, Kuhn W, Muller S, Menon G, Holland L, et al (1996) Enterocolitis and colon cancer in interleukin-10 deficient mice are associated with aberrant cytokine production and CD4+ Th1-like responses. J Clin Invest 98:1010
40. Deventer SJH van, Elson CO, Fedorak RN (1997) Multiple doses of intravenous interleukin-10 in steroid refractory Crohn's disease. Crohn's disease Study Group. Gastroenterology 113:383-389
41. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F (1999) The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117:1433-1437
42. Rutgeerts P, D'Haens GR, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769
43. Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444
44. Mary J-Y, Modigliana R (1989) Development of validation of an endoscopic index of the severity for Crohn's disease: a prospective, multicentre study. Gut 30:983-989
45. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483
46. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804-810
47. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, et al (1993) Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomised mice. Blood 81:901-908
48. Tepler I, Elias L, Smith JW 2nd, Hussein M, Rosen G, Chang AY, et al (1996) A randomized, placebo controlled trial of recombinant human interleukin-11 in cancer patients with severe thromboctyopenia due to cheotherapy. Blood 87:3615-3624
49. Du XX, Doerschuk CM, Orazi A, Williams DA (1994) A bone marrow stromal derived growth factor, interleukin-11 stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83:33-37
50. Potten CS (1996) Protection of the small intestinal clonigenic stem cells from radiation induced damage by pretreatment with interleukin-11 also increases murine survival time. Stem Cells 14:452-459
51. Peterson RL, Wang L, Albert L, Keith JC Jnr, Dorner AJ (1998) Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 78:1503-1512
52. Qiu BS, Pfeiffer CJ, Keith JC Jnr (1996) Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 41:1625-1630
53. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, et al (1991) Cloning of cDNA for natural killer cell stimulatory factor: a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074-3082
54. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, et al (1991) Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88:4143-4147
55. Kobayashi M, Fitz ML, Ryan M, Hewick RM, Clark SC, Chan S, et al (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 170:827-845
56. Trinchieri G (1998) Interleukin-12: a cytokine at the interface between inflammation and immunity. Adv Immunol 70:83-243
57. Sgadari C, et al (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon inducible protein 10. Blood 87:3877-3882
58. Ling P, Gately MK, Gubler U, et al (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor does not mediate biologic activity. J Immunol 154:116-127
59. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al (1997) Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 150:823-832
60. Berrebi D, Besnard M, Fromont-Hankard G, Paris R, Mougenot JF, De Lagausie P, et al (1998) Interleukin-12 expression is focally enhanced in gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol 152:667-672
61. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al (1997) Interleukin-12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169-1178
62. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W (1995) Antibodies to interleukin-12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290
63. Bauditz J, Wedel S, Lochs H (2002) Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50:196-200
64. Okamura HH, Tsutsui H, Komatsu T, Yutsuso A, Hakura T, Tanimoto K, et al (1995) Cloning of a new cytokine that induces IFN-γ production by T-cells. Nature 378:88
65. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, et al (1997) Caspase 1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:623
66. Gu Y, Kuida K, Tsutsui H, Ku G, Hsaio K, Fleming MA, et al (1997) Activation of interferon gamma inducing factor mediated by interleukin-1 beta converting enzyme. Science 275:206-209
67. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, et al (1997) Purification and characterisation of the human interleukin-18 receptor. J Biol Chem 272:25737-25742
68. Born TL, Thomassen E, Bird TA, Sims JE (1998) Cloning of a novel receptor subunit, AcPL, required for interlekin-18 signalling. J Biol Chem 273:29445-29450
69. Thomassen E, Bird TA, Renshaw BR, Kennedy MK, Sims JE (1998) Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp! leads to activation of signalling pathways similar to those used by interleukin-1. J Interferon Cytokine Res 18:1077-1088
70. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubenstein M (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-136
71. Kim SH, Eisenstein M, Reznikov LL, Fantuzzi G, Novick D, Rubenstein M, et al (2000) Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 97:1190-1195
72. Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, et al (2000) Interleukin-18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 119:1514-1523
73. Okamura HH, Kashiwamura S, Isutsui H, Yoshimoto T, Nakanishi K (1998) Regulation of interferon-γ production by IL-12 and IL-18. Curr Opin Immunol 10:259-264
74. Osaki T, et al (1999) Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor interleukin-18 (IL-18). Gene Ther 6:808-815
75. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, et al (1996) Interferon gamma inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon gamma production. Eur J Immunol 26:1647-1651
76. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA (1998) Interleukin-18 enhances lipopolysaccharide induced interferon gamma production in human whole blood cultures. J Infect Dis 178:1830-1834
77. Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M, Ohta T, et al (1997) Interleukin-18 activates NF-κB in murine T-helper type 1 cells. Biochem Biophys Res Commun 234:454-457
78. Sivakamur PV, Westrich GN, Kanaly S, Sims J, Derry J, Viney JL (2001) IL-18 is a primary mediator of inflammation associated with DSS-induced colitis: blocking IL-18 prevents intestinal damage (abstract). Gastroenterology 120:A6g2
79. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, et al (2001) Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production in mice. Gastroenterology 121:1372-1379
80. Camoglio L, Velde AAT, de Boer A, ten Kate FJ, Kopf M, van Deventer SJH (2000) Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN gamma receptor deficient mice. Eur J Immunol 30:1486-1495
81. Fehniger TA, Caligiuri MA (2001) Interleukin-15: biology and relevance to human disease. Blood 97:14-32
82. Grabstein KH, Eisenman J, Shanebeck K, et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965-968
83. Burton JD, Bamford RN, Peters C, et al (1994) A lymphokine, previously designated interleukin T and produced by adult T-cell leukaemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 91:4935-4939
84. Kirman I, Nielsen OH (1996) Increased numbers of IL-15 expressing cells in active ulcerative colitis. Am J Gastroenterol 91:1789-1794
85. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al (2001) Clinical biological and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120:13-20
86. Sakai T, Kusugami N, Nishimura H, Ando T, Yamaguchi T, Ohsuga M, et al (1998) Interleukin-15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 114:1237-1243
87. Liu Z, Gebboes K, Colpaert D, D'Haens GR, Rutgeerts P, Ceuppens JL (2000) Il-15 is highly expressed in inflammatory bowel disease and regulates local T-cell-dependent cytokine production. J Immunol 164:3608-3615
88. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY (1998) Il-15 receptor alpha chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathy. J Immunol 160:5654-5660
89. Kim YS, Maslinski W, Zheng XX, et al (1998) Targeting the Il-15 receptor with an antagonist IL-15 mutant/Fc gamma 2a protein blocks delayed type hypersensitivity. J Immunol 160:5742-5749
90. Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA (2000) IL-15 costimulates the generalised Shwartzman reaction and innate immune IFN-γ production in vivo. J Immunol 164:1643-1647
91. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60-66
92. Hemler ME, Huang C, Takada Y, Schwartz L, Strominger JL, Clabby ML (1987) Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem 262:11478-11485
93. Farstad IN, Halstensen TS, Kvale D, Fausa O, Brandtzaeg P (1997) Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue. Am J Pathol 150:187-199
94. Gordon FH, Lai CWY, Hamilton M, Allison MC, Srivastava ED, Fouweather MG, et al (2001) A randomized placebo controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121:268-274
95. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al (1998) A placebo controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114:1133-1142
96. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al (2001) Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120:1339-1346
97. Shibata Y, Foster LA, Kurimoto M, Okamura HH, Nakamura RM, Kawajiri K, et al (1998) Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-γ inducing factors but enhances NK cell production of IFN-γ. J Immunol 161:4283-4288
98. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJH, Schreiber S, et al (2002) Treatment of Crohn's disease with recombinant human interleukin-10 induces the proinflammatory interferon-γ. Gut 50:191-195
99. Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM (2001) The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol 166:7625-7633
100. Steidler LW, Hans L, Schotte S, Neirynck F, Obermeier W, Falk W, et al (2000) Treatment of colitis by Lactobacillus lactis secreting interleukin-10. Science 289:1352